131 related articles for article (PubMed ID: 17240507)
21. Motexafin gadolinium: a redox active drug that enhances the efficacy of bleomycin and doxorubicin.
Miller RA; Woodburn KW; Fan Q; Lee I; Miles D; Duran G; Sikic B; Magda D
Clin Cancer Res; 2001 Oct; 7(10):3215-21. PubMed ID: 11595717
[TBL] [Abstract][Full Text] [Related]
22. [Synergism of sobuzoxane in combination with doxorubicin against leukemia P388 in mice].
Dai ZQ; Xu JY; Yuan XJ; Cai JC
Zhongguo Yao Li Xue Bao; 1996 Jan; 17(1):69-71. PubMed ID: 8737460
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of anticancer effects of newly synthesized dihydropyridine derivatives in comparison to verapamil and doxorubicin on T47D parental and resistant cell lines in vitro.
Bazargan L; Fouladdel S; Shafiee A; Amini M; Ghaffari SM; Azizi E
Cell Biol Toxicol; 2008 Apr; 24(2):165-74. PubMed ID: 17805981
[TBL] [Abstract][Full Text] [Related]
24. Relationships between the in vitro cytotoxicity and transport characteristics of pirarubicin and doxorubicin in M5076 ovarian sarcoma cells, and comparison with those in Ehrlich ascites carcinoma cells.
Nagai K; Nagasawa K; Sadzuka Y; Tsujimoto M; Takara K; Ohnishi N; Yokoyama T; Fujimoto S
Cancer Chemother Pharmacol; 2002 Mar; 49(3):244-50. PubMed ID: 11935217
[TBL] [Abstract][Full Text] [Related]
25. MMPs-specific PEGylated peptide-DOX conjugate micelles that can contain free doxorubicin.
Lee GY; Park K; Kim SY; Byun Y
Eur J Pharm Biopharm; 2007 Nov; 67(3):646-54. PubMed ID: 17499491
[TBL] [Abstract][Full Text] [Related]
26. Theanine, a specific glutamate derivative in green tea, reduces the adverse reactions of doxorubicin by changing the glutathione level.
Sugiyama T; Sadzuka Y
Cancer Lett; 2004 Aug; 212(2):177-84. PubMed ID: 15279898
[TBL] [Abstract][Full Text] [Related]
27. Overcoming multidrug resistance in human carcinoma cells by an antisense oligodeoxynucleotide--doxorubicin conjugate in vitro and in vivo.
Ren Y; Wang Y; Zhang Y; Wei D
Mol Pharm; 2008; 5(4):579-87. PubMed ID: 18461970
[TBL] [Abstract][Full Text] [Related]
28. Vascular targeting of doxorubicin using cationic liposomes.
Wu J; Lee A; Lu Y; Lee RJ
Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
[TBL] [Abstract][Full Text] [Related]
29. Theanine and glutamate transporter inhibitors enhance the antitumor efficacy of chemotherapeutic agents.
Sugiyama T; Sadzuka Y
Biochim Biophys Acta; 2003 Dec; 1653(2):47-59. PubMed ID: 14643924
[TBL] [Abstract][Full Text] [Related]
30. Extensive intracellular accumulation of ID-6105, a novel anthracycline, in SK-OV-3 ovarian cancer cells.
Shin DH; Choi KS; Park SA; Cho BS; Lee HS; Ryu JS; Kim TY; Lee CK; Song S; Chung YB
Arch Pharm Res; 2008 Oct; 31(10):1355-61. PubMed ID: 18958428
[TBL] [Abstract][Full Text] [Related]
31. A pH/enzyme-responsive tumor-specific delivery system for doxorubicin.
Dong L; Xia S; Wu K; Huang Z; Chen H; Chen J; Zhang J
Biomaterials; 2010 Aug; 31(24):6309-16. PubMed ID: 20472287
[TBL] [Abstract][Full Text] [Related]
32. Experimental immunotherapy of mice with transplanted MC-rhabdomyosarcoma resistant to doxorubicin.
Berezhnaya NM; Kovalchuk EV; Vinnichuk YD; Spivak SI; Belova OB
Eksp Onkol; 2004 Mar; 26(1):63-6. PubMed ID: 15112582
[TBL] [Abstract][Full Text] [Related]
33. Iloprost attenuates doxorubicin-induced cardiac injury in a murine model without compromising tumour suppression.
Neilan TG; Jassal DS; Scully MF; Chen G; Deflandre C; McAllister H; Kay E; Austin SC; Halpern EF; Harmey JH; Fitzgerald DJ
Eur Heart J; 2006 May; 27(10):1251-6. PubMed ID: 16624831
[TBL] [Abstract][Full Text] [Related]
34. Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin.
Pastorino F; Di Paolo D; Piccardi F; Nico B; Ribatti D; Daga A; Baio G; Neumaier CE; Brignole C; Loi M; Marimpietri D; Pagnan G; Cilli M; Lepekhin EA; Garde SV; Longhi R; Corti A; Allen TM; Wu JJ; Ponzoni M
Clin Cancer Res; 2008 Nov; 14(22):7320-9. PubMed ID: 19010847
[TBL] [Abstract][Full Text] [Related]
35. Conjugates of doxorubicin with graft HPMA copolymers for passive tumor targeting.
Etrych T; Chytil P; Mrkvan T; Sírová M; Ríhová B; Ulbrich K
J Control Release; 2008 Dec; 132(3):184-92. PubMed ID: 18534705
[TBL] [Abstract][Full Text] [Related]
36. Synergistic effect of probimane on anticancer cytotoxicity of doxorubicin in vitro.
Zhang Y; Ye QX; Liu J; Zhang ZY; Zhang TM
Zhongguo Yao Li Xue Bao; 1994 Jan; 15(1):56-9. PubMed ID: 8010087
[TBL] [Abstract][Full Text] [Related]
37. Enhanced efficacy of 1-methyl-3-propyl-7-butylxanthine on the antitumor activity of doxorubicin against doxorubicin-resistant P388 leukemia.
Sadzuka Y; Sugiyama T; Sawanishi H; Miyamoto K
Cancer Lett; 1999 Apr; 138(1-2):5-11. PubMed ID: 10378767
[TBL] [Abstract][Full Text] [Related]
38. Experimental study of thalidomide for treatment of murine hepatocellular carcinoma.
Yang YM; Du GJ; Lin HH
Di Yi Jun Yi Da Xue Xue Bao; 2005 Aug; 25(8):925-8. PubMed ID: 16109542
[TBL] [Abstract][Full Text] [Related]
39. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
Li X; Ding L; Xu Y; Wang Y; Ping Q
Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
[TBL] [Abstract][Full Text] [Related]
40. Cardiac DT-diaphorase contributes to the detoxification system against doxorubicin-induced positive inotropic effects in guinea-pig isolated atria.
Badary OA; Awad AS; Abdel-Maksoud S; Hamada FM
Clin Exp Pharmacol Physiol; 2004 Dec; 31(12):856-61. PubMed ID: 15659049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
